Fig. 5
From: Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis
Therapeutic treatment of 2-DG reduced the severity of EAN. The rats were intraperitoneally injected with 2-DG (550 mg/kg) daily from day 10 p.i. (the neurological deficit appeared) to day 21 p.i. (all rats showed signs of recovery). n = 6 in each group (two rats in control group died of respiratory failure). Obvious improvement in the clinical scores (a) and the weight loss (b) were observed in 2-DG group. *p < 0.05, **p < 0.01, ***p < 0.001. c H&E staining of the sciatic nerves on day 21 p.i. (× 200 magnification, arrows denote the inflammatory mononuclear cells). (d) The demyelination was reduced, shown with LFB staining on day 21 p.i. (× 100 magnification). Mean histological scores were calculated as described in the methods and materials part (**p < 0.01) (n = 4 in control group; n = 6 in 2-DG group). e More serious weight loss and paralysis could be observed in the control rat (arrowed) than in the 2-DG-treated rat. The results are expressed as mean ± SD, two-tailed Student’s t test for unpaired data